Development of anti-tumor agents based on biological response modification.
| Project/Area Number |
17016013
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research on Priority Areas
|
| Allocation Type | Single-year Grants |
|---|
| Review Section |
Biological Sciences
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
HASHIMOTO Yuichi The University of Tokyo, 分子細胞生物学研究所, 教授 (90164798)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOBAYASHI Hisayoshi 東京大学, 分子細胞生物学研究所, 助教 (80225531)
NOGUCHI Tomomi 東京大学, 分子細胞生物学研究所, 技術職員 (20401284)
|
|---|
| Project Period (FY) |
2005 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥43,400,000 (Direct Cost: ¥43,400,000)
Fiscal Year 2009: ¥8,600,000 (Direct Cost: ¥8,600,000)
Fiscal Year 2008: ¥8,600,000 (Direct Cost: ¥8,600,000)
Fiscal Year 2007: ¥8,600,000 (Direct Cost: ¥8,600,000)
Fiscal Year 2006: ¥8,600,000 (Direct Cost: ¥8,600,000)
Fiscal Year 2005: ¥9,000,000 (Direct Cost: ¥9,000,000)
|
|---|
| Keywords | がん治療 / 構造展開 / 構造活性相関 / サリドマイド / アポトーシス / 核内受容体 / チュブリン重合阻害剤 / 阻害剤 / 分化誘導 / ペプチダーゼ / 抗アンドロゲン / 血管新生阻害 / ヒストン脱アセチル化酵素 / 核内受容体リガンド / レチノイド / 代謝物 / チュブリン重合阻害 / ビタミンD |
|---|
| Research Abstract |
Various kinds of biologically active compounds were prepared based on biological response modification, so as to avoid possible side effects elicited specifically by cytotoxic anti-tumor agents. Nuclear receptor ligands and thalidomide (and/or its metabolite) were selected as major seeds compounds, and their structural development and activity expansion studies were performed.
|
Report
(6 results)
Research Products
(74 results)
